Euroapi Company Header Euroapi Company Header

X
[{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"$8.2 million","newsHeadline":"Fresh Tracks Announces $8.25 Million Buyout of its Right to Receive Future Sofpironium Bromide Payments from Botanix","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No sweat for dermatology specialist Botanix as hyperhidrosis gel Sofdra gains FDA approval","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Botanix Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Sofdra (sofpironium) works by inhibiting M3 muscarinic receptors in eccrine glands. It is approved for the treatment of primary axillary hyperhidrosis in patients ages 9 and older.

            Lead Product(s): Sofpironium Bromide

            Therapeutic Area: Dermatology Product Name: Sofdra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 20, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Fresh Tracks provided consulting services as an independent contractor to Botanix in support of and through filing and approval of the U.S. new drug application for BBI-4000 (sofpironium bromide gel).

            Lead Product(s): Sofpironium Bromide

            Therapeutic Area: Dermatology Product Name: BBI-4000

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Fresh Tracks Therapeutics

            Deal Size: $8.2 million Upfront Cash: $8.2 million

            Deal Type: Agreement July 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY